AdJane's Intranasal Vaccine Platform Hits First Clinical Milestone

Published in the journal Vaccines, the trial results demonstrate that the intranasal delivery method is safe and well-tolerated. Unlike traditional injectable vaccines, which excel at preventing severe disease but often fail to stop the initial spread of airborne pathogens, AdJane’s platform targets the nasal mucosa—the primary site of infection. Managing Director Anita Gashi noted that this data validates the platform as a next-generation tool for pandemic preparedness and respiratory disease management.

The underlying technology, derived from over three decades of research by Dutch governmental institutions, utilizes vesicles from Neisseria meningitidis. These are modified to enhance safety and manufacturing scalability while maintaining their natural ability to stimulate the immune system. Because the platform acts as a modular system, it allows for the rapid integration of various antigens to combat emerging threats. Beyond respiratory viruses, AdJane is currently leveraging this technology for antimicrobial resistance programs, including a study targeting drug-resistant Neisseria gonorrhoeae supported by CARB-X. The vaccine candidates also remain stable under standard refrigeration for over 2.5 years, a critical factor for global distribution and stockpiling.